Jennison Associates
CAI icon

Jennison Associates’s Caris Life Sciences CAI Stock Holding History

Jennison Associates’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-84,459
Closed -$2.55M – 650
2025
Q3 		$2.55M Sell
84,459
-202,165
-71% -$6.45M ﹤0.01% 416
2025
Q2 		$7.66M Buy
+286,624
New +$7.72M ﹤0.01% 395

Other funds holding CAI

JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jennison Associates's CAI Position: Q4 2025 in Review

Jennison Associates sold out of Caris Life Sciences (CAI) in Q4 2025, closing a stake of 84,459 shares — an estimated $2.55M sold.

Jennison Associates first reported a position in CAI in Q2 2025 and held it in 2 quarters. The position peaked at $7.66M in Q2 2025. 186 funds tracked by Wall St. Rank hold CAI as of Q4 2025.

  • Jennison Associates reported no remaining Caris Life Sciences position as of Q4 2025 after selling out during the quarter.
  • Jennison Associates sold 84,459 Caris Life Sciences shares in Q4 2025, an estimated $2.55M.
  • Jennison Associates first reported a position in Caris Life Sciences in Q2 2025 and held it in 2 quarters.
  • Jennison Associates's Caris Life Sciences position peaked at $7.66M in Q2 2025.
  • 186 funds tracked by Wall St. Rank held Caris Life Sciences as of Q4 2025.

Based on Jennison Associates's 13F filing for Q4 2025, filed 30 Jan 2026.